<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>477</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15364457</PubmedId>
            <Abstract>The efficacy of antibody mediated immunity against Cryptococcus neoformans has not been established experimentally for human antibodies. Our group has previously shown that immunization with a conjugate consisting of a peptide mimotope of the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM), P13, and diphtheria toxoid (P13-DT) prolonged survival of transgenic mice with human immunoglobulin loci, XenoMouse mice, which were challenged with a lethal dose of C. neoformans. In the study reported herein, we determined the efficacy of human antibodies in the sera of immunized XenoMouse mice against C. neoformans in passive transfer experiments in naïve BALB/c mice. Survival studies were performed with sera from XenoMouse mice expressing human IgG2/kappa (G2/k mice) or IgG4/kappa (G4/k mice) that had been immunized with P13-tetanus toxoid (TT)/Alhydrogel with or without CpG, and G2/k mice that had been immunized with P13-DT/Alhydrogel/CpG or Alhydrogel/CpG, obtained on day 7 (early sera) and days 30 or 35-59 (late sera) after primary immunization. Compared to mice receiving sera from G2/k-PBS-treated mice, the survival of naïve mice was prolonged by both early and late sera from G2/k-P13-DT/Alhydrogel/CpG-immunized mice, but only late sera from G2/k-P13-TT/Alhydrogel/CpG-immunized mice. Late, but not early sera from G2/k-Alhydrogel/CpG-immunized mice also prolonged survival. For all sera, prolongation of survival was associated with GXM-specific serum IgM. Sera from G2/k mice that received P13-TT without CpG, and all groups of G4/k mice had low to undetectable levels of antibody to GXM and were not protective. Our findings suggest that GXM-specific human IgM may be a functional mediator of protection against C. neoformans.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>4062-8</ArticlePages>
            <ArticleTitle>Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Maitta</LastName>
                    <ForeName>Robert W</ForeName>
                </Author>
                <Author>
                    <LastName>Datta</LastName>
                    <ForeName>Kausik</ForeName>
                </Author>
                <Author>
                    <LastName>Pirofski</LastName>
                    <ForeName>Liise-Anne</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Adjuvants, Immunologic;Antibodies, Fungal;CPG-oligonucleotide;Immune Sera;Immunoglobulin G;Immunoglobulin M;Immunoglobulin kappa-Chains;Oligodeoxyribonucleotides;Polysaccharides;Tetanus Toxoid;Aluminum Hydroxide;glucuronoxylomannan</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic; Aluminum Hydroxide(immunology); Animals; Antibodies, Fungal(immunology); Cryptococcosis(immunology); Cryptococcus neoformans(immunology); Genes, Immunoglobulin; Immune Sera(immunology); Immunization, Passive; Immunoglobulin G(genetics; immunology); Immunoglobulin M(blood; immunology); Immunoglobulin kappa-Chains(genetics; immunology); Mice; Mice, Inbred BALB C; Mice, Transgenic; Oligodeoxyribonucleotides(immunology); Polysaccharides(immunology); Tetanus Toxoid(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>22</Volume>
                <Issue>29-30</Issue>
                <Title>Vaccine</Title>
                <Issn>0264-410X</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>P13</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>GMDGTQLDRW</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is a mimotope of:</RelatedObjectType>
                    <RelatedObject>
                        <AccessionNonSequenceMolecule>
                            <ChemicalType>Carbohydrate</ChemicalType>
                            <Molecule>
                                <ChEBIId>CHEBI:53457</ChEBIId>
                            </Molecule>
                            <SourceOrganismId>5207</SourceOrganismId>
                        </AccessionNonSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Cited reference</LocationOfData>
                <EpitopeId>21254</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The peptide sequence is obtained from Zhang et al, Infect Immun. 1997 Apr;65(4):1158-64 [PMID: 9119446].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>1505816</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000657</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>GMDGTQLDRW</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>10ug per mouse, administered on days 0, 14 and 38.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Vaccination protocols where described elsewhere. Maitta et al. Infection and Immunity (2004) 72(1) 196-208. [PMID:14688097j.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Serum</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Polyclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyHeavyChainType>IgG4</TransferredAntibodyHeavyChainType>
                                <TransferredAntibodyLightChainType>Kappa</TransferredAntibodyLightChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Mus musculus BALB/c were adoptively transferred with Serum.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer recipient mice were challenged with 5x10^6 CFU of Crytococcus neoformans var neoformans (serotype D, ATCC catalog 24067). For serum obtained from IgG2/k Xenomouse protection is seen concomitantly with the rise in anti-GXM IgM antibody titers. Based on those results and these from IgG4/k Xenomouse, that have low IgM titers, authors conclude that protection is mediated by anti-GXM IgMs.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>40410</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2 and 3</LocationOfData>
                        <BCellId>1505817</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000657</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>GMDGTQLDRW</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC280292</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1717</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>10ug per mouse, administered on days 0, 14 and 28.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Vaccination protocols where described elsewhere. Maitta et al. Infection and Immunity (2004) 72(1) 196-208. [PMID:14688097j.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Serum</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Polyclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyHeavyChainType>IgM</TransferredAntibodyHeavyChainType>
                                <TransferredAntibodyLightChainType>Kappa</TransferredAntibodyLightChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Serum preparations from Xenomouse immunized with or without CpG and with tetanus or diphteria toxins, and obtained after 1 or 3 immunizations were adoptively transfered to Balb/C mice.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Adoptive transfer recipient mice were challenged with 5x10"6 CFU of Crytococcus neoformans var neoformans (serotype D, ATCC catalog 24067). For serum obtained from IgG2/k Xenomouse with diphteria toxin as carrier and Alhydrogel and CpG as adjuvants, protection is seen after one immunization, while for other carrier and adjuvants combinations (tetanus toxoid as carrier, with or without CpG), protection is seen only after 3 immunizations, concomitantly with the rise in anti-GXM IgM antibody titers. Based on those results and those from IgG4/k Xenomouse, that have low IgM titers, authors conclude that protection is mediated by anti-GXM IgMs.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>40410</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1 and 2</LocationOfData>
                        <BCellId>1505814</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000657</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>GMDGTQLDRW</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC280292</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1717</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>10ug per mouse, administered on day 0, 14 and 28.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mice were immunized with the epitope plus or minus CpG.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The response was higher when the epitope was co-administered with CpG.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG2</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:53457</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>5207</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1505812</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000657</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>GMDGTQLDRW</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>AAA23282.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1513</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>10ug per mouse, administered on day 0, 14 and 38.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mice were immunized with the epitope plus or minus CpG.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG4</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:53457</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>5207</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1505815</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000657</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>GMDGTQLDRW</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC280292</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>1717</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Adjuvant>CpG</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>10ug per mouse, administered on day 0, 14 and 28.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The mice were immunized with the epitope plus or minus CpG.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:53457</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>5207</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

